WAY-123783
WAY-123783 is a potent, selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor producing activity after metabolism. WAY-123783 can increase the excretion of sugar in urine and at the same time lower the blood sugar level in db/db mice (ED50 = 9.85 mg/kg). WAY-123783 can be used for the research of metabolic disease, such as diabetes.
For research use only. We do not sell to patients.
- CAS No.: 152595-59-0
- Formula: C12H11F3N2OS
- Molecular Weight:288.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
SGLT2 |
Chemical Information
-
CAS No. 152595-59-0
-
Molecular Weight 288.29
-
Formula C12H11F3N2OS
-
SMILES
O=C1NNC(C(F)(F)F)=C1CC2=CC=C(C=C2)SC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
[1]. Ohsumi K, Matsueda H, Hatanaka T, Hirama R, Umemura T, Oonuki A, Ishida N, Kageyama Y, Maezono K, Kondo N. Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2269-72. [Content Brief]
[2]. Kees KL, et al. New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl)pyrazoles and -pyrazolones. J Med Chem. 1996 Sep 27;39(20):3920-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)